These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 26733381)

  • 1. Entry inhibitors: New advances in HCV treatment.
    Qian XJ; Zhu YZ; Zhao P; Qi ZT
    Emerg Microbes Infect; 2016 Jan; 5(1):e3. PubMed ID: 26733381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entry Inhibitors of Hepatitis C Virus.
    Qian XJ; Qi ZT
    Adv Exp Med Biol; 2022; 1366():207-222. PubMed ID: 35412143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
    Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
    J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Entry inhibitors and future treatment of hepatitis C.
    Fofana I; Jilg N; Chung RT; Baumert TF
    Antiviral Res; 2014 Apr; 104():136-42. PubMed ID: 24525381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.
    Lin LT; Chung CY; Hsu WC; Chang SP; Hung TC; Shields J; Russell RS; Lin CC; Li CF; Yen MH; Tyrrell DL; Lin CC; Richardson CD
    J Hepatol; 2015 Mar; 62(3):541-8. PubMed ID: 25450204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Oxo-1-[(2,3,6,7-tetramethoxy-9-phenanthrenyl)methyl]-L-proline Inhibits Hepatitis C Virus Entry.
    Nguyen LP; Park C; Luong TTD; Park EM; Choi DH; Han KM; Mai HN; Nguyen HC; Lim YS; Hwang SB
    Sci Rep; 2019 May; 9(1):7288. PubMed ID: 31086268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.
    Xiao F; Fofana I; Thumann C; Mailly L; Alles R; Robinet E; Meyer N; Schaeffer M; Habersetzer F; Doffoël M; Leyssen P; Neyts J; Zeisel MB; Baumert TF
    Gut; 2015 Mar; 64(3):483-94. PubMed ID: 24848265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals.
    Colpitts CC; Baumert TF
    Hepatol Int; 2016 Sep; 10(5):741-8. PubMed ID: 27048616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (4R,6S)-2-Dihydromenisdaurilide is a Butenolide that Efficiently Inhibits Hepatitis C Virus Entry.
    Chung CY; Liu CH; Wang GH; Jassey A; Li CL; Chen L; Yen MH; Lin CC; Lin LT
    Sci Rep; 2016 Jul; 6():29969. PubMed ID: 27426693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New HCV therapies on the horizon.
    Vermehren J; Sarrazin C
    Clin Microbiol Infect; 2011 Feb; 17(2):122-34. PubMed ID: 21087349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus entry.
    Zeisel MB; Felmlee DJ; Baumert TF
    Curr Top Microbiol Immunol; 2013; 369():87-112. PubMed ID: 23463198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.
    Vausselin T; Séron K; Lavie M; Mesalam AA; Lemasson M; Belouzard S; Fénéant L; Danneels A; Rouillé Y; Cocquerel L; Foquet L; Rosenberg AR; Wychowski C; Meuleman P; Melnyk P; Dubuisson J
    J Virol; 2016 Oct; 90(19):8422-34. PubMed ID: 27412600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity-based and fraction-guided analysis of Phyllanthus urinaria identifies loliolide as a potent inhibitor of hepatitis C virus entry.
    Chung CY; Liu CH; Burnouf T; Wang GH; Chang SP; Jassey A; Tai CJ; Tai CJ; Huang CJ; Richardson CD; Yen MH; Lin CC; Lin LT
    Antiviral Res; 2016 Jun; 130():58-68. PubMed ID: 27012176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein.
    Hung TC; Jassey A; Liu CH; Lin CJ; Lin CC; Wong SH; Wang JY; Yen MH; Lin LT
    Phytomedicine; 2019 Feb; 53():62-69. PubMed ID: 30668413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
    Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K
    Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors Targeting Hepatitis C Virus (HCV) Entry.
    da Silva Santos-Júnior PF; de Araújo-Júnior JX; da Silva-Júnior EF
    Mini Rev Med Chem; 2023; 23(11):1193-1221. PubMed ID: 37424359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection.
    Rolt A; Le D; Hu Z; Wang AQ; Shah P; Singleton M; Hughes E; Dulcey AE; He S; Imamura M; Uchida T; Chayama K; Xu X; Marugan JJ; Liang TJ
    J Infect Dis; 2018 May; 217(11):1761-1769. PubMed ID: 29373739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry.
    Behrendt P; Perin P; Menzel N; Banda D; Pfaender S; Alves MP; Thiel V; Meuleman P; Colpitts CC; Schang LM; Vondran FWR; Anggakusuma ; Manns MP; Steinmann E; Pietschmann T
    Antiviral Res; 2017 Nov; 147():19-28. PubMed ID: 28923507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.